Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer

A phase III randomized trial was conducted in patients with metastatic NSCLC, to determine if, in association with mitomycin (6 mg m(–2)) and ifosfamide (3 g m(–2)), the combination of moderate dosages of cisplatin (60 mg m(–2)) and carboplatin (200 mg m(–2)) – CarboMIP regimen – improved survival i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sculier, J-P, Lafitte, J-J, Paesmans, M, Thiriaux, J, Alexopoulos, C G, Baumöhl, J, Schmerber, J, Koumakis, G, Florin, M C, Zacharias, C, Berghmans, T, Mommen, P, Ninane, V, Klastersky, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363584/
https://www.ncbi.nlm.nih.gov/pubmed/11027424
http://dx.doi.org/10.1054/bjoc.2000.1413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363584/
https://www.ncbi.nlm.nih.gov/pubmed/11027424
http://dx.doi.org/10.1054/bjoc.2000.1413

Ejemplares similares